Catalepsy induced by the 5-HT1A receptor antagonist WAY 100635 in rats pretreated with the selective serotonin reuptake inhibitor citalopram

被引：3
作者：
Eltayb, A [1 ]
Svensson, TH [1 ]
Ahlenius, S [1 ]
机构：
[1] Karolinska Inst, Dept Physiol & Pharmacol, SE-17177 Stockholm, Sweden
来源：
EUROPEAN JOURNAL OF PHARMACOLOGY | 2001年 / 411卷 / 03期
关键词：
5-HT1A receptors; 5-HT; (5-hydroxytrypytamine; serotonin) reuptake inhibitor; selective; catalepsy; (Rat);
D O I：
10.1016/S0014-2999(00)00924-9
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Neither a high dose of the selective serotonin reuptake inhibitor citalopram (100 mu mol kg(-1) s.c.), nor the 5-HT1A receptor antagonist N-[2-[4-(2-methoxyphenyl)-1-piperaziny]-N-ethyl]-N-(2-pyridinyl) cyclohexane carboxamide 3HCl (WAY 100635) (0.1-0.4 mu mol kg(-1) s.c.) produced any evidence of catalepsy in adult male rats. When combined with citalopram, however. WAY 100635 produced a dose-dependent, and statistically significant, catalepsy in the inclined grid test. (C) 2001 Elsevier Science B.V. All rights reserved.
引用
收藏
页码：275 / 277
页数：3
相关论文
共 50 条
[1]   Synergistic actions of the 5-HT1A receptor antagonist WAY-100635 and citalopram on male rat ejaculatory behavior [J].
Ahlenius, S ;
Larsson, K .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1999, 379 (01) :1-6
[2]   EMD 68843, a serotonin reuptake inhibitor with selective presynaptic 5-HT1A receptor agonistic properties [J].
Bartoszyk, GD ;
Hegenbart, R ;
Ziegler, H .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1997, 322 (2-3) :147-153
[3]   QUANTITATIVE AUTORADIOGRAPHIC CHARACTERIZATION OF THE BINDING OF [H-3] WAY-100635, A SELECTIVE 5-HT1A RECEPTOR ANTAGONIST [J].
KHAWAJA, X .
BRAIN RESEARCH, 1995, 673 (02) :217-225
[4]   Effects of WAY 100635 on antipsychotic-induced catalepsy in 5-HT depleted animals:: a role for tonic activation of 5-HT1A receptors [J].
Prinssen, EPM ;
Koek, W ;
Kleven, MS .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2000, 395 (02) :143-147
[5]   Potentiation of the time-dependent, antidepressant-induced changes in the agonistic behaviour of resident rats by the 5-HT1A receptor antagonist, WAY-100635 [J].
Mitchell, PJ ;
Redfern, PH .
BEHAVIOURAL PHARMACOLOGY, 1997, 8 (6-7) :585-606
[6]   WAY 100635, a 5-HT1A receptor antagonist, prevents the impairment of spatial learning caused by blockade of hippocampal NMDA receptors [J].
Carli, M ;
Silva, S ;
Balducci, C ;
Samanin, R .
NEUROPHARMACOLOGY, 1999, 38 (08) :1165-1173
[7]   Augmentation with a 5-HT1A but not a 5-HT1B receptor antagonist critically depends on the dose of citalopram [J].
Cremers, TIFH ;
de Boer, P ;
Liao, Y ;
Bosker, FJ ;
den Boer, JA ;
Westerink, BHC ;
Wikström, HV .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2000, 397 (01) :63-74
[8]   5-HT1A and 5-HT7 receptor crosstalk in the regulation of emotional memory: Implications for effects of selective serotonin reuptake inhibitors [J].
Eriksson, Therese M. ;
Holst, Sarah ;
Stan, Tiberiu L. ;
Hager, Torben ;
Sjogren, Benita ;
Ogren, Sven Ove ;
Svenningsson, Per ;
Stiedl, Oliver .
NEUROPHARMACOLOGY, 2012, 63 (06) :1150-1160
[9]   Reversal of visual attention dysfunction after AMPA lesions of the nucleus basalis magnocellularis (NBM) by the cholinesterase inhibitor donepezil and by a 5-HT1A receptor antagonist WAY 100635 [J].
C. Balducci ;
M. Nurra ;
A. Pietropoli ;
R. Samanin ;
M. Carli .
Psychopharmacology, 2003, 167 :28-36
[10]   Electrophysiological evidence for rapid 5-HT1A autoreceptor inhibition by vilazodone, a 5-HT1A receptor partial agonist and 5-HT reuptake inhibitor [J].
Ashby, Charles R., Jr. ;
Kehne, John H. ;
Bartoszyk, Gerd D. ;
Renda, Matthew J. ;
Athanasiou, Maria ;
Pierz, Kerri A. ;
Seyfried, Christoph A. .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2013, 714 (1-3) :359-365
12345